Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jubilant Life Sciences Ltd.

www.jubl.com

Latest From Jubilant Life Sciences Ltd.

Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged

A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.

Coronavirus COVID-19 BioPharmaceutical

The Quality Lowdown: Valsartan Options, Supply Chain Warnings, Button Cameras

Yet another valsartan approved as quality/shortage crisis unfolds, while warning letters hit firms on poor root cause investigations and supply chain issues, and FDA investigators procure shirt-button candid cameras.

Manufacturing Quality

Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation

The latest drug development news and highlights from our FDA Performance Tracker.

United States BioPharmaceutical

Sanofi Taps Jubilant Expertise For Metabolic Disorder Drug Discovery

India's biggest contract research firm Jubilant Life Sciences says it has joined forces with the German arm of France's biggest pharma firm Sanofi to discover new therapies for treating metabolic disorders.

BioPharmaceutical India
See All

Company Information

UsernamePublicRestriction

Register